Superior rejection profile during the first 24 months after heart transplantation under tacrolimus as baseline immunosuppressive regimen
Matthias Helmschrott,1 Jan Beckendorf,1 Ceylan Akyol,1 Arjang Ruhparwar,2 Bastian Schmack,2 Christian Erbel,1 Christian A Gleissner,1 Mohammadreza Akhavanpoor,1 Philipp Ehlermann,1 Tom Bruckner,3 Hugo A Katus,1 Andreas O Doesch1 1Department of Cardiology, Angiology, Pneumology, University of Heide...
Main Authors: | , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2014-09-01
|
Series: | Drug Design, Development and Therapy |
Online Access: | http://www.dovepress.com/superior-rejection-profile-during-the-first-24nbspmonths-after-heart-t-peer-reviewed-article-DDDT |
id |
doaj-e253c54146bd4b7ab6a567bbb0e95e6c |
---|---|
record_format |
Article |
spelling |
doaj-e253c54146bd4b7ab6a567bbb0e95e6c2020-11-25T00:42:48ZengDove Medical PressDrug Design, Development and Therapy1177-88812014-09-012014default1307131418250Superior rejection profile during the first 24 months after heart transplantation under tacrolimus as baseline immunosuppressive regimenHelmschrott MBeckendorf JAkyol CRuhparwar ASchmack BErbel CGleissner CAAkhavanpoor MEhlermann PBruckner TKatus HADoesch AO Matthias Helmschrott,1 Jan Beckendorf,1 Ceylan Akyol,1 Arjang Ruhparwar,2 Bastian Schmack,2 Christian Erbel,1 Christian A Gleissner,1 Mohammadreza Akhavanpoor,1 Philipp Ehlermann,1 Tom Bruckner,3 Hugo A Katus,1 Andreas O Doesch1 1Department of Cardiology, Angiology, Pneumology, University of Heidelberg, Heidelberg, Germany; 2Department of Cardiac Surgery, University of Heidelberg, Heidelberg, Germany; 3Institute for Medical Biometry and Informatics, University of Heidelberg, Heidelberg, Germany Background: The use of tacrolimus (TAC) in patients after heart transplantation (HTX) has increased over the last few years. Aim: In this retrospective study, we evaluated the effects of a TAC (conventional and extended-release TAC)-based immunosuppressive therapy regarding rejection profile in comparison to a cyclosporine A (CSA)-based regimen in patients after HTX.Methods: The data of 233 patients who underwent HTX at the Heidelberg Heart Transplantation Center from May 1998 until November 2010 were retrospectively analyzed. Primary immunosuppressive therapy was changed from a CSA (n=114) to a TAC (n=119)-based regimen in February 2006 according to center routine. Follow-up period was 2 years post-HTX. Primary endpoint was time to first biopsy-proven rejection requiring therapy. In all patients, routine follow-up at the Heidelberg Heart Transplantation Center was mandatory. Results: Multivariate risk factor analysis regarding time to first rejection episode showed no statistically significant differences regarding recipient age, donor age, recipient sex, donor sex, sex mismatch, ischemic time, and diagnosis leading to HTX between the two groups (all P= not statistically significant). Time to first biopsy-proven rejection was significantly longer in the TAC group (intention-to-treat analysis, n=233, log-rank test P<0.0001; per-protocol analysis, n=150, log-rank test P=0.0003). In patients who underwent a change of primary immunosuppression (n=49), a significantly longer time to first biopsy-proven rejection was also found in the primary TAC subgroup (log-rank test P=0.0297). Further subgroup analysis in the TAC subgroups showed no statistically significant differences in time to biopsy-proven rejection under extended-release TAC compared to conventional TAC (intention-to-treat analysis, log-rank test P=0.1736).Conclusion: Our study demonstrated that a TAC-based primary immunosuppressive therapy is superior to a CSA-based immunosuppressive regimen in patients after HTX regarding time to first biopsy-proven rejection. Keywords: extended-release tacrolimus, cyclosporine A, renal functionhttp://www.dovepress.com/superior-rejection-profile-during-the-first-24nbspmonths-after-heart-t-peer-reviewed-article-DDDT |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Helmschrott M Beckendorf J Akyol C Ruhparwar A Schmack B Erbel C Gleissner CA Akhavanpoor M Ehlermann P Bruckner T Katus HA Doesch AO |
spellingShingle |
Helmschrott M Beckendorf J Akyol C Ruhparwar A Schmack B Erbel C Gleissner CA Akhavanpoor M Ehlermann P Bruckner T Katus HA Doesch AO Superior rejection profile during the first 24 months after heart transplantation under tacrolimus as baseline immunosuppressive regimen Drug Design, Development and Therapy |
author_facet |
Helmschrott M Beckendorf J Akyol C Ruhparwar A Schmack B Erbel C Gleissner CA Akhavanpoor M Ehlermann P Bruckner T Katus HA Doesch AO |
author_sort |
Helmschrott M |
title |
Superior rejection profile during the first 24 months after heart transplantation under tacrolimus as baseline immunosuppressive regimen |
title_short |
Superior rejection profile during the first 24 months after heart transplantation under tacrolimus as baseline immunosuppressive regimen |
title_full |
Superior rejection profile during the first 24 months after heart transplantation under tacrolimus as baseline immunosuppressive regimen |
title_fullStr |
Superior rejection profile during the first 24 months after heart transplantation under tacrolimus as baseline immunosuppressive regimen |
title_full_unstemmed |
Superior rejection profile during the first 24 months after heart transplantation under tacrolimus as baseline immunosuppressive regimen |
title_sort |
superior rejection profile during the first 24 months after heart transplantation under tacrolimus as baseline immunosuppressive regimen |
publisher |
Dove Medical Press |
series |
Drug Design, Development and Therapy |
issn |
1177-8881 |
publishDate |
2014-09-01 |
description |
Matthias Helmschrott,1 Jan Beckendorf,1 Ceylan Akyol,1 Arjang Ruhparwar,2 Bastian Schmack,2 Christian Erbel,1 Christian A Gleissner,1 Mohammadreza Akhavanpoor,1 Philipp Ehlermann,1 Tom Bruckner,3 Hugo A Katus,1 Andreas O Doesch1 1Department of Cardiology, Angiology, Pneumology, University of Heidelberg, Heidelberg, Germany; 2Department of Cardiac Surgery, University of Heidelberg, Heidelberg, Germany; 3Institute for Medical Biometry and Informatics, University of Heidelberg, Heidelberg, Germany Background: The use of tacrolimus (TAC) in patients after heart transplantation (HTX) has increased over the last few years. Aim: In this retrospective study, we evaluated the effects of a TAC (conventional and extended-release TAC)-based immunosuppressive therapy regarding rejection profile in comparison to a cyclosporine A (CSA)-based regimen in patients after HTX.Methods: The data of 233 patients who underwent HTX at the Heidelberg Heart Transplantation Center from May 1998 until November 2010 were retrospectively analyzed. Primary immunosuppressive therapy was changed from a CSA (n=114) to a TAC (n=119)-based regimen in February 2006 according to center routine. Follow-up period was 2 years post-HTX. Primary endpoint was time to first biopsy-proven rejection requiring therapy. In all patients, routine follow-up at the Heidelberg Heart Transplantation Center was mandatory. Results: Multivariate risk factor analysis regarding time to first rejection episode showed no statistically significant differences regarding recipient age, donor age, recipient sex, donor sex, sex mismatch, ischemic time, and diagnosis leading to HTX between the two groups (all P= not statistically significant). Time to first biopsy-proven rejection was significantly longer in the TAC group (intention-to-treat analysis, n=233, log-rank test P<0.0001; per-protocol analysis, n=150, log-rank test P=0.0003). In patients who underwent a change of primary immunosuppression (n=49), a significantly longer time to first biopsy-proven rejection was also found in the primary TAC subgroup (log-rank test P=0.0297). Further subgroup analysis in the TAC subgroups showed no statistically significant differences in time to biopsy-proven rejection under extended-release TAC compared to conventional TAC (intention-to-treat analysis, log-rank test P=0.1736).Conclusion: Our study demonstrated that a TAC-based primary immunosuppressive therapy is superior to a CSA-based immunosuppressive regimen in patients after HTX regarding time to first biopsy-proven rejection. Keywords: extended-release tacrolimus, cyclosporine A, renal function |
url |
http://www.dovepress.com/superior-rejection-profile-during-the-first-24nbspmonths-after-heart-t-peer-reviewed-article-DDDT |
work_keys_str_mv |
AT helmschrottm superiorrejectionprofileduringthefirst24nbspmonthsafterhearttransplantationundertacrolimusasbaselineimmunosuppressiveregimen AT beckendorfj superiorrejectionprofileduringthefirst24nbspmonthsafterhearttransplantationundertacrolimusasbaselineimmunosuppressiveregimen AT akyolc superiorrejectionprofileduringthefirst24nbspmonthsafterhearttransplantationundertacrolimusasbaselineimmunosuppressiveregimen AT ruhparwara superiorrejectionprofileduringthefirst24nbspmonthsafterhearttransplantationundertacrolimusasbaselineimmunosuppressiveregimen AT schmackb superiorrejectionprofileduringthefirst24nbspmonthsafterhearttransplantationundertacrolimusasbaselineimmunosuppressiveregimen AT erbelc superiorrejectionprofileduringthefirst24nbspmonthsafterhearttransplantationundertacrolimusasbaselineimmunosuppressiveregimen AT gleissnerca superiorrejectionprofileduringthefirst24nbspmonthsafterhearttransplantationundertacrolimusasbaselineimmunosuppressiveregimen AT akhavanpoorm superiorrejectionprofileduringthefirst24nbspmonthsafterhearttransplantationundertacrolimusasbaselineimmunosuppressiveregimen AT ehlermannp superiorrejectionprofileduringthefirst24nbspmonthsafterhearttransplantationundertacrolimusasbaselineimmunosuppressiveregimen AT brucknert superiorrejectionprofileduringthefirst24nbspmonthsafterhearttransplantationundertacrolimusasbaselineimmunosuppressiveregimen AT katusha superiorrejectionprofileduringthefirst24nbspmonthsafterhearttransplantationundertacrolimusasbaselineimmunosuppressiveregimen AT doeschao superiorrejectionprofileduringthefirst24nbspmonthsafterhearttransplantationundertacrolimusasbaselineimmunosuppressiveregimen |
_version_ |
1725280240500998144 |